Nihon Kagaku Pharmaceutical resolved at its Board of Directors meeting on May 12, 2026, to acquire 286,900 shares of treasury stock through market purchases on the Tokyo Stock Exchange, at a total cost of approximately \u00a56.16 billion. The acquisition period is from May 13 to May 31, 2026.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4272","jir_company_name":"Nihon Kagaku Pharmaceutical Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-06-04","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/06\/4272-20260604-01.pdf","jir_short_summary":"Nihon Kagaku Pharmaceutical resolved at its Board of Directors meeting on May 12, 2026, to acquire 286,900 shares of treasury stock through market purchases on the Tokyo Stock Exchange, at a total cost of approximately \u00a56.16 billion. The acquisition period is from May 13 to May 31, 2026.","jir_summary":"### Overview of Capital Policy\nNihon Kagaku Pharmaceutical, following a resolution at its Board of Directors meeting on May 12, 2026, acquired 286,900 shares of treasury stock through market purchases, investing approximately \u00a56.16 billion. The acquisition period is from May 13 to May 31, 2026, with a maximum limit of 13,000,000 shares and a total budget of \u00a51.5 billion. This buyback is part of their shareholder return strategy, aimed at preventing shareholder dilution and enhancing shareholder value.\n\n### Impact on Shareholders and Future Outlook\nFollowing this share buyback, the proportion of treasury stock to total issued shares will be 8.75%. The company intends to continue considering acquisitions of shares and dividend policies as part of its capital management, aiming to improve shareholder value. The acquired shares will be circulated in the market to ensure liquidity and strengthen shareholder returns.","jir_financial_highlights":"Total number of shares acquired: 286,900 shares (Unknown)\nTotal acquisition cost of shares: \u00a5616,642,500 (Unknown)\nType of shares targeted for acquisition: Our common stock (Unknown)","jir_category":"","jir_hashtags":"#NihonKagakuPharmaceutical, #ShareBuyback, #JapaneseStocks","jir_key_figures":"Total shares acquired: 286,900 shares\nTotal acquisition cost: \u00a5616,642,500\nAcquisition period: May 13, 2026 \u2013 May 31, 2026","jir_meta_title":"\u3010Nihon Kagaku Pharmaceutical\u3011Share Buyback of 286,900 shares (~\u00a56.16 billion)\uff5cMay 2026","jir_meta_description":"Nihon Kagaku Pharmaceutical acquired 286,900 shares of treasury stock in May 2026 at approximately \u00a56.16 billion. This is part of their capital policy aimed at shareholder return and capital efficiency enhancement.","jir_og_title":"\u3010Nihon Kagaku Pharmaceutical\u3011Share Buyback\uff5cMay 2026","jir_og_description":"Nihon Kagaku Pharmaceutical acquired 286,900 shares of treasury stock in May 2026 at approximately \u00a56.16 billion. Promoting shareholder return and capital efficiency.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":8762,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"share_buyback","footnotes":""},"sector":[],"importance":[],"class_list":["post-56647","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n